Literature DB >> 191576

Cyclic AMP and adenyl cyclase in brain tumors.

M A Furman, K Shulman.   

Abstract

Some of the regulatory mechanisms of cyclic adenosine monophosphate (AMP) production in human brain tumors were investigated by assessing both cyclic AMP levels and adenyl cyclase activity. A large disparity was found between the levels of cyclic AMP of normal brain and brain-tumor tissue. Cyclic AMP levels were much lower in brain tumors (25.8 pmoles (picomoles)/mg protein) than in normal brain (98.8 pmoles/mg protein). These studies also show that the abnormally low levels of cyclic AMP in tumors parallel those of adenyl cyclase. The mean adenyl cyclase activity of brain tissue was found to be 111.0 pmoles of cyclic AMP/min/mg protein, while that of the tumor was only 23.0 pmoles/min/mg protein. Levels of cyclic AMP and adenyl cyclase activity were inversely related to the degree of malignancy. Attempts to stimulate adenyl cyclase in homogenates of human brain and brain tumors resulted in a similar response in both tissues. Norepinephrone was the most effective stimulant and produced a two- to threefold increase in cyclic AMP production, while histamine had no effect. It is concluded that one of the factors governing tumor growth may be a defect in the adenyl cyclase system.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 191576     DOI: 10.3171/jns.1977.46.4.0477

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  23 in total

1.  Post-transcriptional regulation of PDGFα-receptor in O-2A progenitor cells.

Authors:  Haiying Li; Chiayeng Wang
Journal:  Int J Clin Exp Med       Date:  2011-10-12

2.  {Beta}2-adrenergic receptor agonists inhibit the proliferation of 1321N1 astrocytoma cells.

Authors:  L Toll; L Jimenez; N Waleh; K Jozwiak; A Y-H Woo; R-P Xiao; M Bernier; I W Wainer
Journal:  J Pharmacol Exp Ther       Date:  2010-11-11       Impact factor: 4.030

3.  Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.

Authors:  Patricia Goldhoff; Nicole M Warrington; David D Limbrick; Andrew Hope; B Mark Woerner; Erin Jackson; Arie Perry; David Piwnica-Worms; Joshua B Rubin
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

4.  Subcellular fractionation and distribution of cholinergic binding sites in fetal human brain.

Authors:  J Whyte; R Harrison; G G Lunt; S Wonnacott
Journal:  Neurochem Res       Date:  1986-07       Impact factor: 3.996

Review 5.  Immunobiologic aspects of the brain and human gliomas. A review.

Authors:  C J Wikstrand; D D Bigner
Journal:  Am J Pathol       Date:  1980-02       Impact factor: 4.307

6.  microRNA-200a downregulation in human glioma leads to Gαi1 over-expression, Akt activation, and cell proliferation.

Authors:  Yuan-Yuan Liu; Min-Bin Chen; Long Cheng; Zhi-Qing Zhang; Zheng-Quan Yu; Qin Jiang; Gang Chen; Cong Cao
Journal:  Oncogene       Date:  2018-03-09       Impact factor: 9.867

7.  An experimental trial of cyclic nucleotides on multicellular spheroids derived from human brain tumours.

Authors:  N Oktar; J L Darling; D G Thomas
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

8.  Treating brain tumors with PDE4 inhibitors.

Authors:  Rajarshi Sengupta; Tao Sun; Nicole M Warrington; Joshua B Rubin
Journal:  Trends Pharmacol Sci       Date:  2011-03-28       Impact factor: 14.819

9.  Cyclic nucleotides in experimental and human brain tumors.

Authors:  G Racagni; S Pezzotta; M T Giordana; E Iuliano; I Mocchetti; G Spanu; G Sangiovanni; P Paoletti
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

10.  Role of Rap1B and tumor suppressor PTEN in the negative regulation of lysophosphatidic acid--induced migration by isoproterenol in glioma cells.

Authors:  Enkhzol Malchinkhuu; Koichi Sato; Tomohiko Maehama; Shogo Ishiuchi; Yuhei Yoshimoto; Chihiro Mogi; Takao Kimura; Hitoshi Kurose; Hideaki Tomura; Fumikazu Okajima
Journal:  Mol Biol Cell       Date:  2009-12       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.